German Med-Tech Pioneer Targeting €200 Million in Capital Raise
German medical technology provider Brainlab has announced plans to go public on the Frankfurt Stock Exchange, with a target of raising up to €200 million in capital in the coming weeks. The IPO aims to support Brainlab’s expansion into new clinical fields and strengthen its fast-growing digital health platform, with both new and secondary shares being offered to the market[2][3][4].
Supporting Digital Transformation in Healthcare
Brainlab, headquartered in Munich, is recognized for its innovative software that supports surgeries, tumor radiation therapies, and integrated clinical workflows. Its offerings serve approximately 4,000 healthcare institutions across 120 countries, reinforcing its status as a global leader in healthcare technology[5]. Proceeds from the IPO are expected to:
- Fund development of software for new clinical applications and adjacent healthcare segments
- Accelerate commercialization of integrated medical workflows
- Strengthen the company’s financial foundation for continued digital transformation
Strong Financial Momentum and Leadership Transition
For the first half of its 2024/25 fiscal year, Brainlab recorded revenues of €239 million, achieving an operating profit margin of 22.4%[2][4][5]. These figures underscore the company’s profitable growth and its strategic focus on a software-first business model.
The company, which employs roughly 2,000 people, was founded 35 years ago by Stefan Vilsmeier. Earlier this year, Vilsmeier stepped down from day-to-day operations but remains committed as a long-term investor, a move seen as a vote of confidence in the company’s growth trajectory[2][3].
IPO Details and Market Position
The IPO will be conducted on Frankfurt’s regulated Prime Standard market. Major banks including Berenberg, Deutsche Bank, Commerzbank, Jefferies, and UniCredit are managing the offering, with Evercore acting as an advisor to Brainlab[2][3]. Existing shareholders are also planning to sell part of their holdings to ensure sufficient liquidity in the market.
Implications for Investors and the Industry
Brainlab’s IPO represents a significant opportunity for investors interested in the med-tech sector, especially those focused on cutting-edge applications in surgical and radiological software systems. The planned capital raise is expected to broaden Brainlab’s product reach and reinforce its competitive standing as digital innovation continues to reshape global healthcare[3][4].
For further details on Brainlab’s technology and strategy, visit the company’s
official website.
